Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

Stephen J. Freedland, MD, details which patient populations he orders genomic testing for, and how the tests can address clinical challenges in prostate cancer treatment.

EP: 1.Staging, Grading, and Risk Stratification of Prostate Cancer

EP: 2.Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP: 3.Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP: 4.The Potential for Overtreatment or Undertreatment of Prostate Cancer

Now Viewing

EP: 5.Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

EP: 6.Available Genomic Tests for Clinically Localized Prostate Cancer

EP: 7.Clinical Study Data in Prostate Cancer Genomic Testing

EP: 8.Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

EP: 9.Exciting Emerging Data in Prostate Cancer

Related Videos

Related Content

Advertisement

June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke

The phase 1 study is set to begin later this year.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 19th 2025

Real-world studies compare overall survival between ARPIs in mCSPC

Mehmet Asim Bilen, MD Hannah Clarke

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke

ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.

June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke

Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.

Related Content

Advertisement

June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke

The phase 1 study is set to begin later this year.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 19th 2025

Real-world studies compare overall survival between ARPIs in mCSPC

Mehmet Asim Bilen, MD Hannah Clarke

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke

ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.

June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke

Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.